RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPancreatic cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases

An open trial on lung cancer and pancreatic cancer, registered on ClinicalTrials.gov. Led by Hangzhou Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Hangzhou Cancer Hospital杭州市肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07875465, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed advanced solid malignancies:

    Inclusion criterion 4

    Confirmed liver metastasis (pathologically or by 2 imaging modalities).

    Inclusion criterion 8

  3. ECOG performance status 0-2.

    Inclusion criterion 2

  4. Cohort A: Advanced NSCLC with negative driver genes (EGFR/ALK/ROS1), disease progression during first-line platinum-based doublet chemotherapy combined with PD-1/PD-L1 inhibitors.

    Inclusion criterion 5

    Cohort B: Advanced NSCLC with positive driver genes (EGFR/ALK/ROS1), disease progression during first-line targeted therapy.

    Inclusion criterion 6

    Hematology: Absolute neutrophil count ≥ 1.5 × 10\^9/L, Platelets ≥ 100 × 10\^9/L, Hemoglobin ≥ 90 g/L.

    Inclusion criterion 12

    Liver: Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome or liver metastasis); AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN for liver metastasis).

    Inclusion criterion 13

    Kidney: Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula).

    Inclusion criterion 14

  5. At least 1 measurable intrahepatic target lesion per RECIST v1.1.

    Inclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07875465, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years, male or female.
  • ECOG performance status 0-2.
  • Expected survival ≥ 3 months.
  • Histologically or cytologically confirmed advanced solid malignancies:
  • Cohort A: Advanced NSCLC with negative driver genes (EGFR/ALK/ROS1), disease progression during first-line platinum-based doublet chemotherapy combined with PD-1/PD-L1 inhibitors.
  • Cohort B: Advanced NSCLC with positive driver genes (EGFR/ALK/ROS1), disease progression during first-line targeted therapy.
  • Cohort C: Advanced colorectal or pancreatic cancer, disease progression during no more than two lines of therapy.
  • Confirmed liver metastasis (pathologically or by 2 imaging modalities).
  • At least 1 measurable intrahepatic target lesion per RECIST v1.1.
  • Brain metastases are permitted if radiologically stable.
  • Adequate major organ function within 7 days prior to enrollment:
  • Hematology: Absolute neutrophil count ≥ 1.5 × 10\^9/L, Platelets ≥ 100 × 10\^9/L, Hemoglobin ≥ 90 g/L.
  • Liver: Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome or liver metastasis); AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN for liver metastasis).
  • Kidney: Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula).

Exclusion Criteria:

  • Contraindications to radiotherapy and immune checkpoint inhibitor therapy.
  • Prior unacceptable toxicity following immune checkpoint inhibitor therapy.
  • History of abdominopelvic radiotherapy within 6 months prior to enrollment.
  • Prior anti-tumor adverse events not recovered to CTCAE 5.0 Grade ≤ 1.
  • Active uncontrolled systemic bacterial, viral, or fungal infection.
  • Use of antibiotics, antifungals, antivirals, or antiparasitics within 2 weeks prior to enrollment.
  • Any lesion burden with a maximum diameter > 4 cm.
  • Other standard exclusion criteria (e.g., pregnancy, lactation, severe comorbidities, etc.).

Quoted from ClinicalTrials.gov, NCT07875465, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07875465, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07875465